To assess the efficacy and safety of non-vitamin K antagonist oral anticoagulant rivaroxaban in patients with non-valvular atrial fibrillation

作者
Lijun Qin,Yanhong Mou,Yan Guo
出处
期刊:Postȩpy higieny i medycyny doświadczalnej [Index Copernicus International S.A.]
卷期号:79 (1): 145-158
标识
DOI:10.2478/ahem-2025-0018
摘要

Abstract Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) such as rivaroxaban offer potential advantages over warfarin in patients with non-valvular atrial fibrillation (NVAF). However, long-term real-world data evaluating their efficacy and safety, particularly in high-risk subgroups, remain limited. Materials and Methods This prospective observational cohort study enrolled 140 patients with newly diagnosed NVAF receiving rivaroxaban (20 mg daily or 15 mg daily in cases of renal impairment) for stroke prevention. Clinical, biochemical, and echocardiographic parameters were collected at baseline and monitored over 12 months. Primary efficacy and safety endpoints included stroke/systemic embolism and major bleeding (ISTH criteria), respectively. Secondary endpoints included TIA, cardiovascular hospitalization/mortality, non-major bleeding, renal/hepatic dysfunction, and treatment discontinuation. Kaplan-Meier survival analysis and multivariate logistic regression were used to evaluate outcomes and predictors. Results Stroke and systemic embolism occurred in 3.57% and 0.71% of patients, respectively. Major bleeding occurred in 5.71%, including gastrointestinal (2.86%) and intracranial (1.43%) events. Clinically relevant non-major bleeding and minor bleeding were reported in 8.57% and 12.86% of patients, respectively. Treatment was discontinued in 10% due to adverse events, primarily bleeding and renal function deterioration. Regression analysis identified age, CHA 2 DS 2 -VASc, HAS-BLED score, renal impairment, low hemoglobin, and prior stroke/TIA as independent predictors of adverse outcomes. Conclusions Rivaroxaban demonstrated favorable efficacy and acceptable safety in NVAF patients, including elderly and comorbid populations. Bleeding and renal dysfunction were notable risks. Close monitoring and individualized risk stratification remain essential for optimizing anticoagulation outcomes in real-world clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
JSL发布了新的文献求助10
2秒前
2秒前
Mint发布了新的文献求助10
3秒前
Xiao完成签到 ,获得积分10
4秒前
快乐的鱼发布了新的文献求助10
5秒前
圈圈关注了科研通微信公众号
5秒前
没得发布了新的文献求助10
5秒前
5秒前
Jasper的应助被SSSSCCCCIIII采纳,获得30
5秒前
6秒前
JamesPei的应助被吴宣京采纳,获得10
7秒前
LN完成签到 ,获得积分10
8秒前
9秒前
乐乐的应助被zakka采纳,获得10
9秒前
9秒前
十一完成签到 ,获得积分10
9秒前
李博宇发布了新的文献求助10
11秒前
11秒前
彭于晏的应助被番茄炒蛋采纳,获得10
11秒前
13秒前
OxO完成签到,获得积分0
13秒前
14秒前
kimodi完成签到 ,获得积分10
16秒前
SSSSCCCCIIII发布了新的文献求助30
16秒前
马达发布了新的文献求助20
16秒前
17秒前
vnewgnl的应助被李博宇采纳,获得10
17秒前
可乐的应助被李博宇采纳,获得10
17秒前
NexusExplorer的应助被qiuyutingchan采纳,获得10
17秒前
Lucas的应助被qiuyutingchan采纳,获得10
18秒前
搜集达人的应助被qiuyutingchan采纳,获得10
18秒前
吴宣京完成签到,获得积分10
18秒前
在水一方的应助被qiuyutingchan采纳,获得10
18秒前
18秒前
18秒前
Jasper的应助被qiuyutingchan采纳,获得10
18秒前
Wei的应助被qiuyutingchan采纳,获得10
19秒前
jay的应助被qiuyutingchan采纳,获得10
19秒前
圈圈发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928